These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 25028783)

  • 1. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis.
    Chapiro J; Wood LD; Lin M; Duran R; Cornish T; Lesage D; Charu V; Schernthaner R; Wang Z; Tacher V; Savic LJ; Kamel IR; Geschwind JF
    Radiology; 2014 Dec; 273(3):746-58. PubMed ID: 25028783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver.
    Mannelli L; Kim S; Hajdu CH; Babb JS; Clark TW; Taouli B
    AJR Am J Roentgenol; 2009 Oct; 193(4):1044-52. PubMed ID: 19770328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.
    Chapiro J; Duran R; Lin M; Schernthaner RE; Wang Z; Gorodetski B; Geschwind JF
    Radiology; 2015 May; 275(2):438-47. PubMed ID: 25531387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: Prediction and assessment of response to transarterial chemoembolization. Preliminary experience.
    Mannelli L; Kim S; Hajdu CH; Babb JS; Taouli B
    Eur J Radiol; 2013 Apr; 82(4):577-82. PubMed ID: 23246330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging.
    Kamel IR; Liapi E; Reyes DK; Zahurak M; Bluemke DA; Geschwind JF
    Radiology; 2009 Feb; 250(2):466-73. PubMed ID: 19188315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.
    Kamel IR; Bluemke DA; Eng J; Liapi E; Messersmith W; Reyes DK; Geschwind JF
    J Vasc Interv Radiol; 2006 Mar; 17(3):505-12. PubMed ID: 16567675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data.
    Bonekamp S; Jolepalem P; Lazo M; Gulsun MA; Kiraly AP; Kamel IR
    Radiology; 2011 Sep; 260(3):752-61. PubMed ID: 21771960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
    Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
    Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.
    Tacher V; Lin M; Duran R; Yarmohammadi H; Lee H; Chapiro J; Chao M; Wang Z; Frangakis C; Sohn JH; Maltenfort MG; Pawlik T; Geschwind JF
    Radiology; 2016 Jan; 278(1):275-84. PubMed ID: 26131913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
    Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
    J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study.
    Kokabi N; Camacho JC; Xing M; Edalat F; Mittal PK; Kim HS
    J Magn Reson Imaging; 2015 Oct; 42(4):981-9. PubMed ID: 25683022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization.
    Riaz A; Lewandowski RJ; Kulik L; Ryu RK; Mulcahy MF; Baker T; Gates V; Nayar R; Wang E; Miller FH; Sato KT; Omary RA; Abecassis M; Salem R
    Cardiovasc Intervent Radiol; 2010 Dec; 33(6):1143-52. PubMed ID: 19967371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation.
    Labeur TA; Runge JH; Klompenhouwer EG; Klümpen HJ; Takkenberg RB; van Delden OM
    Abdom Radiol (NY); 2019 Aug; 44(8):2740-2750. PubMed ID: 31069479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of Gd-EOB-DTPA-Enhanced MRI and Diffusion-Weighted Imaging in Detecting Residual Hepatocellular Carcinoma After Drug-Eluting Bead Transarterial Chemoembolization.
    Liu HF; Xu YS; Liu Z; Che KY; Sheng Y; Ding JL; Zhang JG; Lei JQ; Xing W
    Acad Radiol; 2021 Jun; 28(6):790-798. PubMed ID: 32414638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using intravoxel incoherent motion (IVIM) MR imaging to predict lipiodol uptake in patients with hepatocellular carcinoma following transcatheter arterial chemoembolization: a preliminary result.
    Park YS; Lee CH; Kim JH; Kim IS; Kiefer B; Seo TS; Kim KA; Park CM
    Magn Reson Imaging; 2014 Jul; 32(6):638-46. PubMed ID: 24703575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of treatment response of chemoembolization in hepatocellular carcinoma with diffusion-weighted imaging on 3.0-T MR imaging.
    Sahin H; Harman M; Cinar C; Bozkaya H; Parildar M; Elmas N
    J Vasc Interv Radiol; 2012 Feb; 23(2):241-7. PubMed ID: 22019180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of diffusion weighted imaging with the quantitative apparent diffusion coefficient in diagnosing residual or recurrent hepatocellular carcinoma after transarterial chemoembolization: a meta-analysis.
    Liu Z; Fan JM; He C; Li ZF; Xu YS; Li Z; Liu HF; Lei JQ
    Cancer Imaging; 2020 Jan; 20(1):3. PubMed ID: 31907050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma.
    Bonekamp D; Bonekamp S; Halappa VG; Geschwind JF; Eng J; Corona-Villalobos CP; Pawlik TM; Kamel IR
    Eur J Radiol; 2014 Mar; 83(3):487-96. PubMed ID: 24387824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator?
    Goshima S; Kanematsu M; Kondo H; Yokoyama R; Tsuge Y; Shiratori Y; Onozuka M; Moriyama N
    J Magn Reson Imaging; 2008 Apr; 27(4):834-9. PubMed ID: 18383261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.